Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO
Study Type: Prevention
Phase: II
NCTID: NCT02679144
Principal Investigator:
Kevin Ginn
Multi-Center Randomized Controlled Phase 2b Clinical Trial To Evaluate The Safety And Efficacy Of Tvi-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Compared To Standard Therapy As A Treatment For Newly Diagnosed O6 -Methylguanine Methyltransferase Negative MGMT Unmethylated Grade 4 Astrocytoma Glioblastoma Multiforme; GBM
Study Type: Treatment
Phase: II
NCTID: NCT05685004
Principal Investigator:
Tolga Tuncer
Phase II Trial of Tremelimumab in Patients with Metastatic Urothelial Cancer Previously Treated with PD-1/PD-L1 Blockade
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Study Type: Treatment
Phase: II
NCTID: NCT03115333
Principal Investigator:
Tolga Tuncer
A Phase III Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy SRT versus Surgically Targeted Radiation Therapy STaRT with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Study Type: Treatment
Phase: III
NCTID: NCT05095376
Principal Investigator:
Tolga Tuncer
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
Study Type: Treatment
Phase: III
NCTID: NCT04166409
Principal Investigator:
Keith August
A Phase II Trial of sEphB4-HSA in Combination with Anti PD1 Antibody Pembrolizumab, MK-3475 for Solid Tumors
Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
Study Type: Other
Phase: Feasibility/Pilot
NCTID: NCT03610906
Principal Investigator:
Kevin Ginn